Assistant Professor of Medicine, University S Fla College of Medicine
Hematology
Dr. Melissa Alsina, MD
|
|
Give Review
Melissa Alsina works in the field of Hematology. She went to University of Puerto Rico School of Medicine. Dr. Melissa Alsina is also published. She has 20 publications published. The lastest publication: "Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experie...' She accepts all Medicare patients.
Publications
- Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic Cell transplantation: a single institution experie...
- Ofatumumab in combination with glucocorticoids for primary therapy of Chronic graft vs. host disease: Phase I trial results.
- An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
- Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation.
- Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic Cell transplantation in patients with multiple myeloma.
- A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
- Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma.
- Immunotherapy strategies for multiple myeloma: the present and the future.
- Sequence of novel agents in multiple myeloma: An instrumental variable Analysis.
- High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.
- Phase II study of CD4+guided pentostatin lymphodepletion and pharmacokinetically-targeted busulfan as conditioning for hematopoietic Cell allografting.
- Allogeneic hematopoietic Cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma.
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
- Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: a Focus on Hematopoietic Cell Transplantation.
- A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic Cell transplantation.
- Stemness of B-Cell Progenitors in Multiple Myeloma Bone Marrow.
- Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.
Schools
University Of Puerto Rico School Of Medicine Medical Sciences Campus
Vet Affairs Med Center
San Juan Hospital Puerto RicoHematology
University Of Texas Health Science CenterHematologyOncology
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
San Juan City Hospital -
University of Puerto Rico School of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1184656746 | |
| NPPES Provider LastName | ALSINA | |
| NPPES Provider FirstName | MELISSA | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 803.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 89.0 | |
| Percent Opioid Claims | 11.08 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184656746 |
| Last Name Of The Provider | ALSINA |
| First Name Of The Provider | MELISSA |
| View All |
Similar Doctors
|
Dr. Mayer Fishman, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Frank B. Lane Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hatem Soliman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Teresa L. Field, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ankita K. Shah, MD |
|
Dr. Javier A. Pinilla-Ibarz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Darrin Beaupre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danny Nguyen, MD |
|
|
Dr. Omayra Reyes Santiago, MD |
|
|
Dr. Richard D. Hall Jr., MD |
|
|
Dr. Monique Z. Sajjad, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teruo Yamauchi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet M. McNaughton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vishakha A. Kale, MD
This Doctor is OpenDoctor Recommended.
|